RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Works matching IS 0344-5704 AND VI 90 AND IP 2 AND DT 2022
Results: 8
1
2
Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
3
Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
4
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies.
- Published in:
- 2022
- By:
- Publication type:
- journal article
5
Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors.
- Published in:
- 2022
- By:
- Publication type:
- journal article
6
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg.
- Published in:
- 2022
- By:
- Publication type:
- journal article
7
Mouse pharmacokinetics and metabolism of the phenylurea thiocarbamate NSC 161128.
- Published in:
- 2022
- By:
- Publication type:
- journal article
8
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article